Intravitreal injections: A review of the evidence for best practice: Response

Clinical and Experimental Ophthalmology

Volumn 42, Issue 1, 2014, Pages 98-100

  Fagan, Xavier J ^a,b   Al Qureshi, Salmaan ^a,b  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ANESTHESIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED PRACTICE; EYE INJURY; HUMAN; INSURANCE; INTRAVITREAL DRUG ADMINISTRATION; LETTER; META ANALYSIS (TOPIC); OUTPATIENT; PAIN; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; SAMPLE SIZE; TRAUMATIC CATARACT; TRAUMATIC LENS INJURY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; HUMANS; INTRAVITREAL INJECTIONS; VITREOUS BODY;

EID: 84892509887     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12258     Document Type: Letter

References (17)

1. Mason JO III, White MF, Feist RM etal. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28: 564-567.
2. Bhavsar AR, Googe JM Jr, Stockdale CR etal. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the Diabetic Retinopathy Clinical Research Network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009; 127: 1581-1583.
3. D'Amico DJ, Masonson HN, Patel M etal. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992-1001.
4. McCannel CA. Meta-analysis of endophthalmitis after intra-vitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011; 31: 654-661.
5. Moshfeghi DM, Kaiser PK, Scott IU. Acute endophthalmitis following intravitreal triamcinolone acetonide Injection. Am J Ophthalmol 2003; 126: 791-796.
6. Bhavsar AR, Ip MS, Glassman AR. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007; 144: 454-456.
7. Meyer CH, Mennel S, Eter N. [Incidence of endophthalmitis after intravitreal avastin injection with and without postoperative topical antibiotic application]. Ophthalmol 2007; 104: 952-957 (article in German).
8. Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol 2012; 96: 1474-1478.
9. Rosenfeld PJ, Brown DM, Heier JS etal. Ranibizimuab for age related macular degeneration. N Engl J Med 2006; 344: 1419-1431.
10. McCannel CA, Meredith T, Peskin E etal. Incidence of endophthalmitis after anti-VEGF injections and use of anti-microbials in the Comparison of AMD Treatment Trials (CATT). Invest Ophthalmol Vis Sci 2013; 54. ARVO E-Abstract C009. 1114-C0091.
11. Brown DM, Nguyen QD, Marcus DM etal. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology 2013; 120: 2013-2022.
12. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012; 153: 196-203.
13. Davis MJ, Pollack JS, Shott S. Comparison of topical anesthetics for intravitreal injections: a randomized clinical trial. Retina 2012; 32: 701-705.
14. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmol 2012; 119: 1609-1614.
15. Brown DM, Kaiser PK, Michels M etal. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
16. Meyer CH, Rodrigues EB, Michels S etal. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010; 26: 491-495.
17. Meyer CH, Michels S, Rodrigues EB etal. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial growth factor injections. Acta Ophthamol 2011; 89: 70-75.